ABOUT

At Nivien, we are driven to help people with cancer and other diseases live longer, healthier lives. 

We are a startup from the IndieBio Accelerator and Harvard Innovation Labs with a therapeutic strategy based on novel biology from Harvard Medical School.

Our molecules harness the potential of the Hippo-YAP signaling pathway to treat cancer and other indications where Hippo plays an important role. We have patented the first inhibitors of the LATS1/2 kinases and are currently in preclinical testing for several cancers.

​

​

​

Cancer Resistance 

Defeating mechanisms that resistant, difficult-to-treat cancers use to evade drug-induced cell death

​

Tissue Repair 

Overcoming irreversible tissue damage such as fibrosis to promote healthier, better-functioning organs

​

Cardiac Regeneration

Increasing cell proliferation to improve cardiac function after myocardial infarction

NIVIEN

FOUNDERS

NATHANIEL BROOKS HORWITZ

CEO

DHARMENDRA SINGH, PH.D.

Scientist, Cancer Biology

NIKITA SHAH

President & CFO

W. KEN FANG, PH.D.

SVP, Medicinal Chemistry

ADVISORS

MARC KIRSCHNER, PH.D.

Harvard Medical School

MOTAZ QADAN, M.D., PH.D.

Massachusetts General Hospital

DERRICK ROSSI, PH.D.

Boston Children's Hospital

INVESTORS

Contact Us

​

Email

nathaniel@generalbiotechnologies.com

nikita@generalbiotechnologies.com

​

Nivien at the IndieBio Accelerator

479 Jessie Street, San Francisco

California, 94103

​

Nivien at the Harvard Innovation Labs

125 Western Avenue, Boston

Massachusetts, 02163

​

​